Thank you. So a bit more details on the numbers. Like Jouni covered, 3.1% growth in the last quarter of the year. There was no impact on the last quarter. But for the whole year, looking at the whole year sales almost at the same level as last year, reported sales is actually down by 0.4%. Also, the gross margin rather stable, within the quarter and full year. Well, actually, the whole year is down, 1.3%. But when you look at the impact, during the last couple of years there, actually last year, the FX, there was a headwind, for €1.6 million for us compared to 2022, there's a tailwind for €6 million. So it's actually a quite big impact on our numbers. In the last quarter we didn't have any non-recurring costs, but for the whole year we incurred 1 million, non-recurring costs for certain one-time projects. So when you look at the quarterly numbers, the reported and the adjusted are the same numbers. But for the whole year, the adjusted EBIT is actually, 28.3 million, 27.3 million and 28.3% of sales. The EBIT percentage is down 2.3%. Um, if you look at the gross margin, it's down 1.3%. So, the biggest part of that is actually the gross margin that has brought down the profitability. Also, the OpEx is impacting 41%. Um, the year-end was extremely good. Um, considering that, like we discussed earlier, we didn't have the microperimeter products in our portfolio this year. So we ran out of stock. Um, and we've been catching up that gap in Q3 and Q4. Uh, looking at the trend line. Um, Q1 and Q4 are pretty much on the trend line as we've seen in earlier years. But as we know, the second and third quarter were below the trend. And that has been the challenge for us for the whole year. Uh, the Q4 sales performance is actually quite good when you leave out the macroperimeters. So there was double-digit growth for the main products that we had in the portfolio that we could sell. Uh, it's double-digit, actually closer to 15 than to ten. Uh, so a quite good finish for the year. Also, the profitability for the last quarter was the highest we've had so far, 9.5 million. Um, basically, more than one-third of the profitability for the whole year was generated in the last quarter. Um, there are a few reasons. Basically, the sales mix, but also the operating costs increased during the whole year quite moderately. So for the whole year, our OpEx is up 3.3% year over year. Uh, so there you can see the scalable business model going also in the other direction. Uh, not only when we grow, but also when we have had a tougher time on the top line. We've also been able to scale the costs. Uh, most of that is actually, as we discussed earlier, the variable bonus payments are quite low for last year. So, that is one driver for the higher profitability. Uh, looking at this year. Maybe that's something that, if we assume that we keep our guidance, the bonus pool is definitely going to be a lot bigger than last year. Um, but also, as we've discussed earlier, the iCare DRSplus and iCare ILLUME FDA clinical trials are ongoing, and we have the new media coming out with the clinical trials. So we'll have more clinical trial costs in our P&L this year, which is something just to keep in mind going forward. So it's something that actually goes through the P&L and we don't put it on the balance sheet. So it's going to be impacting the profitability this year. Uh, but the good thing is it's a one-time cost. So to say, well, they will go away then the following year. Uh, cash flow. Um, so the Q4 wasn't as good as we would have hoped. Um, but of course, there's maybe a good reason for that. So we did have a really good end of the year. Uh, the AR increased significantly. Uh, so due to these larger deals and overall, uh, we had finished extremely well. And then, of course, the Q4 sales are significantly higher than the Q3 sales. So, so, uh, the AR did go up. And that's the main reason why the cash flow, operating cash flow was, was lower in Q4, for the whole year, we also saw working capital changes and then the, uh, certain tax payments in Q2 that partly related to earlier years, uh, was the other reason why the operating cash flow didn't develop as favorably as we've seen before. But I'm sure, uh, Q1 hopefully will be better. Then maybe it'll turn to the other direction when we collect the money. That is outstanding. Um, balance sheet remains very strong. Um, the equity ratio is again at its highest. That's been, uh, so 72.7% net gearing. Uh, -3.6. So we have 21.5 million in the bank at the end of the year. And then interest-bearing debt of, uh, a little bit under 18 million. So the net debt position is -3.6 million. Uh, that we have at the end of the year. Um, the board will propose to the AGM, um, that we will pay a dividend of $0.38 per share. Uh, that roughly adds up to slightly above 10 million. On the shareholders, there's actually, uh, very little change. Surprisingly, it's not often that it's so stable. Um, basically the Finnish ownership has gone down by 0.4%. Um, and basically all the ten names on the list are pretty much the same, but maybe one or 2 have changed, uh, positions or places. So, so nothing much to report here. And then for the guidance, revenue group's exchange rate, adjusted net sales are estimated to grow 5 to 10% from the previous year, and profitability, excluding non-recurring items, is estimated to remain at a good level. And then we're good for questions. Yeah.